[S,S]-Reboxetine Dose-Range Finding Trial

NCT ID: NCT00288652

Last Updated: 2011-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effectiveness of different doses of \[S,S\]-Reboxetine in the treatment of chronic pain following a shingles infection

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[S,S]-Reboxetine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have pain present for more than 3 months after the healing of shingles skin rash
* Patients at screening must have a score \>/=40 mm on the pain visual analogue scale

Exclusion Criteria

* Patients with significant renal and hepatic impairment
* Patients with other severe pain, that may impair the self-assessment of the pain due to shingles
* Patients with clinically abnormal electrocardiogram
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Huntsville, Alabama, United States

Site Status

Pfizer Investigational Site

Chandler, Arizona, United States

Site Status

Pfizer Investigational Site

Mesa, Arizona, United States

Site Status

Pfizer Investigational Site

Phoenix, Arizona, United States

Site Status

Pfizer Investigational Site

Sun City, Arizona, United States

Site Status

Pfizer Investigational Site

Tucson, Arizona, United States

Site Status

Pfizer Investigational Site

Hot Springs, Arkansas, United States

Site Status

Pfizer Investigational Site

Arcadia, California, United States

Site Status

Pfizer Investigational Site

Fullerton, California, United States

Site Status

Pfizer Investigational Site

Irvine, California, United States

Site Status

Pfizer Investigational Site

Laguna Hills, California, United States

Site Status

Pfizer Investigational Site

Loma Linda, California, United States

Site Status

Pfizer Investigational Site

Orange, California, United States

Site Status

Pfizer Investigational Site

Redondo Beach, California, United States

Site Status

Pfizer Investigational Site

Whittier, California, United States

Site Status

Pfizer Investigational Site

Boulder, Colorado, United States

Site Status

Pfizer Investigational Site

Bradenton, Florida, United States

Site Status

Pfizer Investigational Site

Clearwater, Florida, United States

Site Status

Pfizer Investigational Site

Fort Myers, Florida, United States

Site Status

Pfizer Investigational Site

Holly Hill, Florida, United States

Site Status

Pfizer Investigational Site

Hollywood, Florida, United States

Site Status

Pfizer Investigational Site

Kissimmee, Florida, United States

Site Status

Pfizer Investigational Site

Largo, Florida, United States

Site Status

Pfizer Investigational Site

Longwood, Florida, United States

Site Status

Pfizer Investigational Site

Melbourne, Florida, United States

Site Status

Pfizer Investigational Site

Ocala, Florida, United States

Site Status

Pfizer Investigational Site

Oviedo, Florida, United States

Site Status

Pfizer Investigational Site

Palm Beach Gardens, Florida, United States

Site Status

Pfizer Investigational Site

Plantation, Florida, United States

Site Status

Pfizer Investigational Site

Chicago, Illinois, United States

Site Status

Pfizer Investigational Site

Oak Brook, Illinois, United States

Site Status

Pfizer Investigational Site

Evansville, Indiana, United States

Site Status

Pfizer Investigational Site

Topeka, Kansas, United States

Site Status

Pfizer Investigational Site

Ruston, Louisiana, United States

Site Status

Pfizer Investigational Site

Towson, Maryland, United States

Site Status

Pfizer Investigational Site

Boston, Massachusetts, United States

Site Status

Pfizer Investigational Site

Brockton, Massachusetts, United States

Site Status

Pfizer Investigational Site

Ann Arbor, Michigan, United States

Site Status

Pfizer Investigational Site

Southaven, Mississippi, United States

Site Status

Pfizer Investigational Site

Independence, Missouri, United States

Site Status

Pfizer Investigational Site

Kansas City, Missouri, United States

Site Status

Pfizer Investigational Site

Nixa, Missouri, United States

Site Status

Pfizer Investigational Site

Sprinfield, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

Billings, Montana, United States

Site Status

Pfizer Investigational Site

Clifton, New Jersey, United States

Site Status

Pfizer Investigational Site

Hackensack, New Jersey, United States

Site Status

Pfizer Investigational Site

Teaneck, New Jersey, United States

Site Status

Pfizer Investigational Site

Sante Fe, New Mexico, United States

Site Status

Pfizer Investigational Site

Albany, New York, United States

Site Status

Pfizer Investigational Site

Amherst, New York, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

Orchard Park, New York, United States

Site Status

Pfizer Investigational Site

Rochester, New York, United States

Site Status

Pfizer Investigational Site

Asheville, North Carolina, United States

Site Status

Pfizer Investigational Site

Raleigh, North Carolina, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Fargo, North Dakota, United States

Site Status

Pfizer Investigational Site

Canfield, Ohio, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Cleveland, Ohio, United States

Site Status

Pfizer Investigational Site

Columbus, Ohio, United States

Site Status

Pfizer Investigational Site

Kettering, Ohio, United States

Site Status

Pfizer Investigational Site

Toledo, Ohio, United States

Site Status

Pfizer Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Pfizer Investigational Site

Allentown, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Altoona, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Duncansville, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Jackson, Tennessee, United States

Site Status

Pfizer Investigational Site

Kingsport, Tennessee, United States

Site Status

Pfizer Investigational Site

Austin, Texas, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

Norfolk, Virginia, United States

Site Status

Pfizer Investigational Site

Richmond, Virginia, United States

Site Status

Pfizer Investigational Site

Seattle, Washington, United States

Site Status

Pfizer Investigational Site

Spokane, Washington, United States

Site Status

Pfizer Investigational Site

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A6061026

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RN624 For Pain Of Post-Herpetic Neuralgia
NCT00568321 COMPLETED PHASE2